Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Caisson Biotech LLC
Profile last edited on: 12/15/15      CAGE: 5K2G8      UEI:

Business Identifier: drug delivery systems
Year Founded
2009
First Award
2011
Latest Award
2011
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

11412 Bee Caves Road Suite 300
Austin, TX 78738
   (512) 697-8195
   N/A
   www.caissonbiotech.com
Location: Single
Congr. District: 25
County: Travis

Public Profile

Caisson Biotech, LLC, a wholly owned subsidiary spun out of Heparinex LLC.,developed a novel, heparosan-based drug delivery technology, HEPtune™. HEPtune conjugates the polymer heparosan to a drug which enhances the therapeutic properties of pharmaceuticals by increasing product half-life, reducing immunogenicity, and increasing stability.

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$282,450
Phase II Dollars
$0
Total Awarded
$282,450

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2011 1 NIH $282,450
Project Title: Hepylated G-Csf: Drug With Safer, Enhanced Delivery For Neutropenia Treatment

Key People / Management

  Thomas Harlan -- CEO

  Glenn Nedwin -- CEO And President

  Breca Tracy -- Managing Director

  Paul DeAngelis -- Chief Scientist

  Cameron Mackie -- Vice President of Marketing

  Jing Wei

Company News

Mar 11 2014
Caisson Biotech Expands HEPtune™ Drug Delivery Deal with Novo Nordisk
Mar 11 2014
Austin biotech company inks expanded deal with global pharma giant